Psychopharmacology

, Volume 175, Issue 2, pp 215–219 | Cite as

Suicidality and second generation anytipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period

  • Y Barak
  • I Mirecki
  • HY Knobler
  • Z Natan
  • D Aizenberg
Original Investigation

Abstract

Rationale

Rates of attempted suicide for individuals with schizophrenia are approaching 30%. Attempted suicide is among the most potent predictors of subsequent suicide. Several studies suggest that suicide is more likely to occur in patients who are not being adequately treated or not being treated at all. An effort was made in the last decade to evaluate the antisuicide effects of pharmacological treatment in schizophrenia with emphasis on the role of the newer second-generation antipsychotics (SGA).

Objective

The aim of the present study was to assess in a large cohort of schizophrenia patients the effects of exposure to SGA on suicidality of patients suffering from schizophrenia or schizoaffective disorder. The study is a retrospective case-controlled evaluation over a 5-year period undertaken in a large university affiliated tertiary care psychiatric hospital.

Methods

Between January 1998 and December 2002, all records of admissions of schizophrenia or schizoaffective disorder patients (ICD-10) were assessed. Data as to age, gender, diagnosis, suicide attempt prior to admission, treatment with antipsychotic medication, dose and duration of treatment (mg daily, duration) with SGA was extracted from patients’ files. All patients who had attempted suicide prior to admission were defined as the index group. The case-controlled group was comprised of the next admission of a patient suffering from schizophrenia (or schizoaffective disorder), matched for gender and age, who did not attempt suicide.

Results

Records of 756 patients (4486 admissions for said period) were analyzed (56.6% male, mean age 39.1±13.5 years). Amongst 378 patients who attempted suicide (index group), 16.1% were exposed to SGA while 37% were exposed in the control group (P=0.0001). The protective effect (odds ratio) of treatment by SGA was 3.54 (95%CI: 2.4–5.3). Risperidone was more frequently prescribed in the control group (54.3%) and had a larger effect-size than olanzapine (3.16 versus 1.76), although not statistically significant. Clozapine was prescribed only to a few patients.

Conclusions

Schizophrenia patients exposed to both risperidone and olanzapine may gain protection from suicidality. The antisuicide effects seem to differ between SGAs. The long duration and large sample size support this finding, despite the retrospective nature of this study.

Keywords

Antipsychotics Schizophrenia Suicide Case-controlled study 

References

  1. Aleman A, Kahn RS (2001) Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. Eur Neuropsychopharmacol 11:289–293CrossRefPubMedGoogle Scholar
  2. Allebeck P (1989) Schizophrenia: a life-shortening disease. Schizophr Bull 15:81–89PubMedGoogle Scholar
  3. Altamura AC, Bignotti S, Pioli R, Tura G, Mannu P, Soddu A, La Croce L (1999) Suicidal behavior in schizophrenia: a retrospective study. Eur Neuropsychopharmacol 9:S271Google Scholar
  4. Altamura AC, Bassetti R, Bignotti S, Pioli R, Mundo E (2003) Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res 60:47–55CrossRefPubMedGoogle Scholar
  5. Caldwell C, Gottesman I (1990) Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 16:571–589PubMedGoogle Scholar
  6. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia. Am J Psychiatry 158:518–526PubMedGoogle Scholar
  7. Ciapparelli A, Dell’Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB (2000) Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 61:329–334PubMedGoogle Scholar
  8. Conley RR, Mahmoud R (2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 158:765–774CrossRefPubMedGoogle Scholar
  9. De Hert M, McKenzie K, Peuskens J (2001) Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophr Res 47:127–134CrossRefPubMedGoogle Scholar
  10. Duggan A, Warner J, Knapp M, Kerwin R (2003) Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry 182:505–508CrossRefPubMedGoogle Scholar
  11. FDA (2003) Clozaril approved for reducing risk of suicide. FDA Consum 37:5Google Scholar
  12. Fleischhacker WW, Oehl MA, Hummer M (2003) Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 64:10–13Google Scholar
  13. Foster RH, Goa KL (1999) Olanzapine:a pharmacoeconomic review of its use schizophrenia. Pharmacoeconomics 15:61–640Google Scholar
  14. Glazer WM (1998) Formulary decisions and health economics. J Clin Psychiatry 59:23–29Google Scholar
  15. Heilä H, Isometsa ET, Henrikkson MM, Heikkinen ME, Marttuneen MJ, Lonqvist JK (1997) Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 154:1235–1242PubMedGoogle Scholar
  16. Herings RMC, Erkens JA (2003) Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Safety 12:423–424CrossRefGoogle Scholar
  17. Jibson MD, Tandon R (2000) Treatment of schizophrenia. Psychiatr Clin N Am 7:83–113Google Scholar
  18. Keck Jr PE, Strakowski SM, McElroy SL (2000) The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 61:4–9Google Scholar
  19. Khan A, Khan SR, Lenthal RM, Brown WA (2001) Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 158:1449–1454CrossRefPubMedGoogle Scholar
  20. Marder SR (2003) Overview of partial compliance. J Clin Psychiatry 64:3–9Google Scholar
  21. Mauskopf J, Muroff M, Gibson PJ, Grainger DL (2002) Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia. Schizophr Bull 28:619–635PubMedGoogle Scholar
  22. Meltzer HY (2001) Treatment of suicidality in schizophrenia. Ann N Y Acad Sci 932:44–58PubMedGoogle Scholar
  23. Meltzer HY (2002) Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatr Rep 4:279–283Google Scholar
  24. Meltzer HY, Dev VJ (2002) Suicidality during quetiapine treatment: a risk-benefit assessment. Poster presented in the 155th APAGoogle Scholar
  25. Meltzer HY, Alphs L, Altamura AC, Anand R, Bertoli R, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkins S (2003) International suicide prevention trial (InterSePT): reduced suicidality in schizophrenia with clozapine treatment. Arch Gen Psychiatry 59:82–91Google Scholar
  26. Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000) Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45:21–28CrossRefPubMedGoogle Scholar
  27. Peuskens J, Van Baelen B, De Smedt C, Lemmens P (2000) Effect of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 15:343–349PubMedGoogle Scholar
  28. Robins DA, Regier LN (1991) Psychiatric disorders in America. Free Press, New York, p 50Google Scholar
  29. SAS/STAT (1990) Users’ guide, version 6, 4th edn, vols 1, 2. SAS Institute, Cary, N.C.Google Scholar
  30. Sernyak MJ, Desai R, Stolar M, Rosenheck R (2001) Impact of clozapine on completed suicide. Am J Psychiatry 158:931–937PubMedGoogle Scholar
  31. Tamam L, Ozpoyraz N (2001) Suicide during clozapine treatment: a case report. Isr J Psychiatr Relat Sci 38:127–132Google Scholar
  32. Tandon R, Jibson MD (2003) Suicidal behavior in schizophrenia: diagnosis, neurobiology, and treatment implications. Curr Opin Psychiatry 16:193–197CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Y Barak
    • 1
    • 2
  • I Mirecki
    • 1
  • HY Knobler
    • 2
  • Z Natan
    • 1
  • D Aizenberg
    • 3
  1. 1.Abarbanel Mental Health CenterBat-YamIsrael
  2. 2.IDF, Mental HealthIsrael
  3. 3.Geha Mental Health CenterPetah-TikvaIsrael

Personalised recommendations